Global Regulatory and Scientific Policy, The Healthcare Business of Merck KGaA, Darmstadt, Germany. *Corresponding Author: Marén U. Koban, Global Regulatory Affairs, The Healthcare Business of Merck ...
Search for other works by this author on: ...
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
University of Nebraska Medical Center, Omaha, NE, ...
According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the ESMO Congress in Barcelona, Spain, and concurrently published, the Daiichi Sankyo/Astra Zeneca ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback